Table 1.
Mean 24hr Uterine Activity (UA) and Amniotic Fluid Prostaglandins, Cytokines and Leukocytes before and after U. parvum Inoculation and with AZI alone or AZI plus DEX/INDO Treatment.
| Ureaplasma parvum (n=16) | AZI alone (n=5) | AZI plus DEX/INDO (n=5) | ||||
|---|---|---|---|---|---|---|
| Variable | Baseline | Peak Concentration |
Pre–Treatment Concentration |
Post–Treatment Concentration |
Pre–Treatment Concentration |
Post–Treatment Concentration |
| UA (mmHg.sec/h) | 268 ± 31 | 1,295 ± 228# | 969 ± 423 | 347 ± 120* | 1,451 ± 438 | 285 ± 47* |
| PGE2 (pg/ml) | 83 ± 13 | 5,830 ± 1,800# | 2,821 ± 1,458 | 1,145 ± 535* | 3,810 ± 1,541 | 191 ± 135* |
| PGF2α (pg/ml) | 84 ± 12 | 2,099 ± 480# | 1,372 ± 368 | 556 ± 212* | 2,358 ± 1,213 | 166 ± 42* |
| TNF–α (pg/ml) | 31 ± 20 | 1,255 ± 374# | 1,227 ± 441 | 39 ± 26* | 927 ± 155 | 22 ± 13* |
| IL–1β (pg/ml) | 30 ± 16 | 859 ± 243# | 209 ± 98 | 25 ± 16* | 786 ± 251 | 6 ± 5* |
| IL–6 (ng/ml) | 5 ± 2 | 98 ± 27# | 146 ± 54 | 19 ± 10* | 167 ± 34 | 9 ± 2* |
| IL–8 (ng/ml) | 1 ± 1 | 56 ± 20# | 81 ± 52 | 30 ± 24* | 97 ± 22 | 14 ± 5* |
| Leukocytes (cells/µl) | 25 ± 6 | 3,015 ± 601# | 1,840 ± 675 | 594 ± 248* | 2,796 ± 571 | 540 ± 129* |
Data are Mean ± SEM. Concentrations of amniotic fluid pro–inflammatory mediators (n=16) represent peak levels during IAI (range: 6–21 days), or levels prior to treatment (range: 6–8 days of IAI). Post-treatment levels represent minimum concentrations during the 10–day AZI treatment protocol.
Significant compared to baseline pre–infection (P<0.05, n=16)
Significant compared to pre–treatment (P<0.05, n=5 each AZI group).
Abbreviations: AZI, Azithromycin; DEX, Dexamethasone; INDO, Indomethacin; UA, Uterine Activity; PGE2, Prostaglandin E2; PGF2α, Prostaglandin F2α; TNF–α, Tumor Necrosis Factor; IL, Interleukin.